Ernexa Therapeutics price to free cash flow ERNA

Market value divided by free cash flow over the last twelve months, since 2013.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 8.4×; Aug 2020
9-year median: 6.3×
9-year range: 1.2× to 131×
Peer median: 9.5×

Ernexa Therapeutics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Aug 2020, at 8.4×.

On the days it had one over the last 9 years, its median was 6.3×, from 1.2× in Apr 2020 to 131× in Jul 2018.

Price to free cash flow over time

median 6.3×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2020	8.4×	1.2×	13.3×
2019	3.0×	3.0×	16.5×
2018	121×	24.9×	131×
2017	25.0×	6.0×	32.8×
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	72.2×	27.7×	87.2×
2013	28.7×	28.7×	38.6×

Against its peers

Companies in Healthcare nearest Ernexa Therapeutics' size, closest first, today.

Company	Price to free cash flow
ERNAErnexa Therapeutics	n/m
OXBROXBRIDGE RE HOLDINGS	n/m
EDUCEducational Development	49.2×
GTIMGood Times Restaurants	5.2×
MDRRMedalist Diversified	n/m
BCGBinah Capital	3.2×
VIPVulcan Infrastructure & Power	n/m
MXCMexco Energy	13.7×
CKXCKX Lands	n/m
MSGMMotorsport Games	n/m
ATCHAtlasClear	n/m
Peer median	9.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Ernexa Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.